chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Administration site discolouration, Allergy test, Condition aggravated, Erythema, Feeling hot
Clinical narrative: swelling up the injection site; redness; lots of soreness; 4x4 discoloration area on her arm and underneath it; The lymph nodes under her arm became rock hard, and was the size of her palm; the symptoms are becoming worse each day; The area itched terribly it was warm and swollen.; This is a spontaneous report from a contactable other HCP (patient). A 79-year-old female patient received bnt162b2 (COMIRNATY), Dose 2 via an unspecified route of administration on 01Oct2021 (Batch/Lot number was not reported) as a single dose for COVID-19 immunisation. Medical history included allergy to chemicals from an unknown date and unknown if ongoing (PEG 2000), and a vocal cord issue that makes it hard to understand her. The patient's concomitant medications were not reported.  The patient previously took polysorbate 80 and experienced drug hypersensitivity. The patient previously received Dose 1 of bnt162b2 in Sep2021 for covid-19 immunisation and experienced sore arm for 3 days. The patient experienced swelling up the injection site on 02Oct2021, redness on 02Oct2021, lots of soreness on 02Oct2021, 4x4 discoloration area on her arm and underneath it on 02Oct2021, the lymph nodes under her arm became rock hard, and was the size of her palm (medically significant) in 02Oct2021, the symptoms are becoming worse each day (condition aggravated) (medically significant) in Oct2021, the area itched terribly it was warm and swollen in Oct2021. The patient reported she got the second dose on Friday 01Oct2021 and on Saturday, 02Oct2021, the swelling started at the injection site. By Wednesday 06Oct2021, the swelling had spread to the side. There was increased redness, and lots of soreness. She said there was a 4x4 discoloration area on her arm and underneath it. The lymph nodes under her arm became rock hard and was the size of her palm. She said the symptoms are becoming worse each day. That following Monday 10Oct2021, she saw the doctor and she put her on prednisone 40mg daily and the redness kept spreading. The area itched terribly it was warm and swollen. She is going to ask for an antibody test to see if the prednisone nullified the Covid-19 vaccine. She also mentioned that she got tested to check if she was allergic to PEG 2000, but it came back negative. Outcome of the events was unknown.   The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.; Sender's Comments: Based on the information provided, the contributory role of the suspect product bnt162b2 (COMIRNATY), to reported events Lymphadenopathy and condition aggravated is possible. Case will be reassessed upon receipt of follow-up information.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymphadenopathy, Pain, Vaccination site swelling
Clinical narrative: swelling up the injection site; redness; lots of soreness; 4x4 discoloration area on her arm and underneath it; The lymph nodes under her arm became rock hard, and was the size of her palm; the symptoms are becoming worse each day; The area itched terribly it was warm and swollen.; This is a spontaneous report from a contactable other HCP (patient). A 79-year-old female patient received bnt162b2 (COMIRNATY), Dose 2 via an unspecified route of administration on 01Oct2021 (Batch/Lot number was not reported) as a single dose for COVID-19 immunisation. Medical history included allergy to chemicals from an unknown date and unknown if ongoing (PEG 2000), and a vocal cord issue that makes it hard to understand her. The patient's concomitant medications were not reported.  The patient previously took polysorbate 80 and experienced drug hypersensitivity. The patient previously received Dose 1 of bnt162b2 in Sep2021 for covid-19 immunisation and experienced sore arm for 3 days. The patient experienced swelling up the injection site on 02Oct2021, redness on 02Oct2021, lots of soreness on 02Oct2021, 4x4 discoloration area on her arm and underneath it on 02Oct2021, the lymph nodes under her arm became rock hard, and was the size of her palm (medically significant) in 02Oct2021, the symptoms are becoming worse each day (condition aggravated) (medically significant) in Oct2021, the area itched terribly it was warm and swollen in Oct2021. The patient reported she got the second dose on Friday 01Oct2021 and on Saturday, 02Oct2021, the swelling started at the injection site. By Wednesday 06Oct2021, the swelling had spread to the side. There was increased redness, and lots of soreness. She said there was a 4x4 discoloration area on her arm and underneath it. The lymph nodes under her arm became rock hard and was the size of her palm. She said the symptoms are becoming worse each day. That following Monday 10Oct2021, she saw the doctor and she put her on prednisone 40mg daily and the redness kept spreading. The area itched terribly it was warm and swollen. She is going to ask for an antibody test to see if the prednisone nullified the Covid-19 vaccine. She also mentioned that she got tested to check if she was allergic to PEG 2000, but it came back negative. Outcome of the events was unknown.   The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.; Sender's Comments: Based on the information provided, the contributory role of the suspect product bnt162b2 (COMIRNATY), to reported events Lymphadenopathy and condition aggravated is possible. Case will be reassessed upon receipt of follow-up information.
Age: 53.0
Sex: M
Vaccine: FLU4, VARZOS, FLU4, VARZOS
Symptoms: Herpes zoster, Neuralgia, Rash, Rash papular, Skin abrasion
Clinical narrative: shingles; band-like red rash on torso from chest to back, hip to rib cage; band-like raised rash; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 53-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included QUADRIVALENT INFLUENZA VACCINES (AFLURIA QUAD) for prophylaxis.   On 17th September 2021, the patient received the 1st dose of Shingrix (intramuscular) and AFLURIA QUAD (intramuscular). In September 2021, 1 week after receiving Shingrix, the patient experienced shingles, red rash and raised rash. The patient was treated with valaciclovir (Valacyclovir). On an unknown date, the outcome of the shingles, red rash and raised rash were recovered/resolved.   It was unknown if the reporter considered the shingles, red rash and raised rash to be related to Shingrix.  Additional details were provided as follows: This case was reported by the patient himself. The patient received the first dose of Shingrix on the right arm intramuscularly along with the Flu vaccine (Afluria Quad) on the left arm intramuscularly. A week later the patient developed shingles.  He reported a red, raised rash on right side of torso, a band-like rash that extended from chest to back, and hip to rib cage.   In September 2021, 1 week after receiving Flu vaccine (Afluria Quad), the patient experienced shingles, red rash and raised rash. The health care professional had provided Valcyclovir.  The patient mentioned he was finished with the medication and he had almost fully recovered. The patient spoke per content.  It was unknown if the reporter considered the shingles, red rash and raised rash to be related to Flu vaccine (Afluria Quad). The reporter did not consent to followup.
Age: 53.0
Sex: M
Vaccine: FLU4, VARZOS, FLU4, VARZOS
Symptoms: Herpes zoster, Rash, Rash erythematous, Rash papular
Clinical narrative: shingles; band-like red rash on torso from chest to back, hip to rib cage; band-like raised rash; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 53-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included QUADRIVALENT INFLUENZA VACCINES (AFLURIA QUAD) for prophylaxis.   On 17th September 2021, the patient received the 1st dose of Shingrix (intramuscular) and AFLURIA QUAD (intramuscular). In September 2021, 1 week after receiving Shingrix, the patient experienced shingles, red rash and raised rash. The patient was treated with valaciclovir (Valacyclovir). On an unknown date, the outcome of the shingles, red rash and raised rash were recovered/resolved.   It was unknown if the reporter considered the shingles, red rash and raised rash to be related to Shingrix.  Additional details were provided as follows: This case was reported by the patient himself. The patient received the first dose of Shingrix on the right arm intramuscularly along with the Flu vaccine (Afluria Quad) on the left arm intramuscularly. A week later the patient developed shingles.  He reported a red, raised rash on right side of torso, a band-like rash that extended from chest to back, and hip to rib cage.   In September 2021, 1 week after receiving Flu vaccine (Afluria Quad), the patient experienced shingles, red rash and raised rash. The health care professional had provided Valcyclovir.  The patient mentioned he was finished with the medication and he had almost fully recovered. The patient spoke per content.  It was unknown if the reporter considered the shingles, red rash and raised rash to be related to Flu vaccine (Afluria Quad). The reporter did not consent to followup.
Age: 26.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Anxiety, Condition aggravated, Dizziness, Visual impairment
Clinical narrative: Patient started to become lightheaded at around 10 mins after vaccine. Patient lied down with head elevated. Patients vitals stable at 135/90, pulse 75, pulse ox 99, and temp 96.9. Patient remained lying flat with head elevated for an additional 30 mins. With no relief. Gave patient juice and crackers and recheck vitals, which remained stable. No other symptoms reported by patient. No SOB, chest tightness, itchiness, sore throat, tingling or numbness, or headache. Patient continued to feel lightheaded/seeing spots and remained feeling anxious. Patient was evaluated by PCP and was advised to be seen in ER. Patient refused ambulance and will be driven by significant other to ER
Age: 26.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Anxiety, Dizziness, Visual impairment
Clinical narrative: Patient started to become lightheaded at around 10 mins after vaccine. Patient lied down with head elevated. Patients vitals stable at 135/90, pulse 75, pulse ox 99, and temp 96.9. Patient remained lying flat with head elevated for an additional 30 mins. With no relief. Gave patient juice and crackers and recheck vitals, which remained stable. No other symptoms reported by patient. No SOB, chest tightness, itchiness, sore throat, tingling or numbness, or headache. Patient continued to feel lightheaded/seeing spots and remained feeling anxious. Patient was evaluated by PCP and was advised to be seen in ER. Patient refused ambulance and will be driven by significant other to ER
Age: 26.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cold sweat, Dizziness
Clinical narrative: Patient started to become lightheaded at around 10 mins after vaccine. Patient lied down with head elevated. Patients vitals stable at 135/90, pulse 75, pulse ox 99, and temp 96.9. Patient remained lying flat with head elevated for an additional 30 mins. With no relief. Gave patient juice and crackers and recheck vitals, which remained stable. No other symptoms reported by patient. No SOB, chest tightness, itchiness, sore throat, tingling or numbness, or headache. Patient continued to feel lightheaded/seeing spots and remained feeling anxious. Patient was evaluated by PCP and was advised to be seen in ER. Patient refused ambulance and will be driven by significant other to ER
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Constipation, Headache, Illness, Nausea, Pain
Clinical narrative: Severe body ache; Severe nausea; Swollen face; Vomit; Arm pain; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06May2021 at 12:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. On 06May2021 at 12:45, the patient experienced severe bodyache, severe nausea, swollen face, vomit and arm pain. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe bodyache, severe nausea, swollen face, vomit and arm pain was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: Severe body ache; Severe nausea; Swollen face; Vomit; Arm pain; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06May2021 at 12:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. On 06May2021 at 12:45, the patient experienced severe bodyache, severe nausea, swollen face, vomit and arm pain. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe bodyache, severe nausea, swollen face, vomit and arm pain was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Nausea, Pain, Pain in extremity, Swelling face, Vomiting
Clinical narrative: Severe body ache; Severe nausea; Swollen face; Vomit; Arm pain; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06May2021 at 12:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. On 06May2021 at 12:45, the patient experienced severe bodyache, severe nausea, swollen face, vomit and arm pain. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe bodyache, severe nausea, swollen face, vomit and arm pain was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood test normal, Computerised tomogram normal, Electroencephalogram normal, Feeling abnormal, Illness
Clinical narrative: Patient received pfizer booster and then started to suffer from seizures and was in the ER
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Impaired driving ability, Magnetic resonance imaging normal, Nausea, Seizure, Vomiting
Clinical narrative: Patient received pfizer booster and then started to suffer from seizures and was in the ER
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Seizure
Clinical narrative: Patient received pfizer booster and then started to suffer from seizures and was in the ER
Age: 30.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Cognitive disorder, Dizziness, Hyperhidrosis, Neurological symptom, Pallor
Clinical narrative: After receiving the first dose of the COVID-19 vaccine, Dr was alerted that Patient was in the back of the room and not feeling well. When Dr approached Patient, she noticed that his was pale and not responding to questions.  At this time, we asked someone to call ER and Dr joined Dr in the back of the room. Dr approached Mr and also noticed his pale complexion, his lack of verbal responses, and was beginning to sweat. As Dr went to retrieve the emergency medical kit, Dr began rubbing Patient's sternum and yelling his name, attempting to illicit a response. At this point, Patient's briefly lost consciousness. Dr continued rubbing his sternum, patting him on the back and yelling his name. Mr continued breathing the entire episode. After a few moments, Mr regained consciousness and although groggy, was orientated times 4 (person, place, time, and situation). At this point, emergency personnel arrived and proceeded to assess Patient After a brief examination and interview, Mr decided that he did not want to be transported to a hospital.     Dr also discussed with Patient's the need for him to see a healthcare provider to alert him of this episode and to receive a checkup to rule out other health conditions. Patient remained in the vaccination area for about an hour, received a snack and beverages, and was dismissed to his work area after he informed Drs that he was feeling better. Dr  contact Patient on Thursday and he informed her that he was feeling much better.
Age: 30.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Vibratory sense increased
Clinical narrative: After receiving the first dose of the COVID-19 vaccine, Dr was alerted that Patient was in the back of the room and not feeling well. When Dr approached Patient, she noticed that his was pale and not responding to questions.  At this time, we asked someone to call ER and Dr joined Dr in the back of the room. Dr approached Mr and also noticed his pale complexion, his lack of verbal responses, and was beginning to sweat. As Dr went to retrieve the emergency medical kit, Dr began rubbing Patient's sternum and yelling his name, attempting to illicit a response. At this point, Patient's briefly lost consciousness. Dr continued rubbing his sternum, patting him on the back and yelling his name. Mr continued breathing the entire episode. After a few moments, Mr regained consciousness and although groggy, was orientated times 4 (person, place, time, and situation). At this point, emergency personnel arrived and proceeded to assess Patient After a brief examination and interview, Mr decided that he did not want to be transported to a hospital.     Dr also discussed with Patient's the need for him to see a healthcare provider to alert him of this episode and to receive a checkup to rule out other health conditions. Patient remained in the vaccination area for about an hour, received a snack and beverages, and was dismissed to his work area after he informed Drs that he was feeling better. Dr  contact Patient on Thursday and he informed her that he was feeling much better.
Age: 30.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Hyperhidrosis, Loss of consciousness, Malaise, Pallor, Somnolence
Clinical narrative: After receiving the first dose of the COVID-19 vaccine, Dr was alerted that Patient was in the back of the room and not feeling well. When Dr approached Patient, she noticed that his was pale and not responding to questions.  At this time, we asked someone to call ER and Dr joined Dr in the back of the room. Dr approached Mr and also noticed his pale complexion, his lack of verbal responses, and was beginning to sweat. As Dr went to retrieve the emergency medical kit, Dr began rubbing Patient's sternum and yelling his name, attempting to illicit a response. At this point, Patient's briefly lost consciousness. Dr continued rubbing his sternum, patting him on the back and yelling his name. Mr continued breathing the entire episode. After a few moments, Mr regained consciousness and although groggy, was orientated times 4 (person, place, time, and situation). At this point, emergency personnel arrived and proceeded to assess Patient After a brief examination and interview, Mr decided that he did not want to be transported to a hospital.     Dr also discussed with Patient's the need for him to see a healthcare provider to alert him of this episode and to receive a checkup to rule out other health conditions. Patient remained in the vaccination area for about an hour, received a snack and beverages, and was dismissed to his work area after he informed Drs that he was feeling better. Dr  contact Patient on Thursday and he informed her that he was feeling much better.
Age: 30.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Unresponsive to stimuli
Clinical narrative: After receiving the first dose of the COVID-19 vaccine, Dr was alerted that Patient was in the back of the room and not feeling well. When Dr approached Patient, she noticed that his was pale and not responding to questions.  At this time, we asked someone to call ER and Dr joined Dr in the back of the room. Dr approached Mr and also noticed his pale complexion, his lack of verbal responses, and was beginning to sweat. As Dr went to retrieve the emergency medical kit, Dr began rubbing Patient's sternum and yelling his name, attempting to illicit a response. At this point, Patient's briefly lost consciousness. Dr continued rubbing his sternum, patting him on the back and yelling his name. Mr continued breathing the entire episode. After a few moments, Mr regained consciousness and although groggy, was orientated times 4 (person, place, time, and situation). At this point, emergency personnel arrived and proceeded to assess Patient After a brief examination and interview, Mr decided that he did not want to be transported to a hospital.     Dr also discussed with Patient's the need for him to see a healthcare provider to alert him of this episode and to receive a checkup to rule out other health conditions. Patient remained in the vaccination area for about an hour, received a snack and beverages, and was dismissed to his work area after he informed Drs that he was feeling better. Dr  contact Patient on Thursday and he informed her that he was feeling much better.
Age: 74.0
Sex: F
Vaccine: FLUA4, FLUA4
Symptoms: Arthralgia, Gait inability, Immunisation reaction, Joint swelling, Synovial cyst
Clinical narrative: VACCINE WAS GIVEN ON 10/04/21 AND PT EXPIERENCED PAIN ON BACK OF LEFT KNEE. CALLED PHARMACIST AND PRIMARY DR AND BOTH TOLD HER HAD A HIGH CHANCE OF BEING AN ADVERSE REACTION TO MED. PAIN DID NOT GO AWAY . SHE WENT TO ORTHOPEDIC ON 10/28/21 AND WAS DIAGNOSED OF HAVING A BAKERS CYST. SHE CAME TO PHARMACY AND I INFORMED HER WE WILL FILL OUT VAERS FORM . SHE HAS NEVER RECEIVED THIS VACCINE OR A HIGH DOSE PREVIOUS TO THIS .
Age: 74.0
Sex: F
Vaccine: FLUA4, FLUA4
Symptoms: X-ray limb abnormal
Clinical narrative: VACCINE WAS GIVEN ON 10/04/21 AND PT EXPIERENCED PAIN ON BACK OF LEFT KNEE. CALLED PHARMACIST AND PRIMARY DR AND BOTH TOLD HER HAD A HIGH CHANCE OF BEING AN ADVERSE REACTION TO MED. PAIN DID NOT GO AWAY . SHE WENT TO ORTHOPEDIC ON 10/28/21 AND WAS DIAGNOSED OF HAVING A BAKERS CYST. SHE CAME TO PHARMACY AND I INFORMED HER WE WILL FILL OUT VAERS FORM . SHE HAS NEVER RECEIVED THIS VACCINE OR A HIGH DOSE PREVIOUS TO THIS .
Age: 74.0
Sex: F
Vaccine: FLUA4, FLUA4
Symptoms: Arthralgia, Synovial cyst
Clinical narrative: VACCINE WAS GIVEN ON 10/04/21 AND PT EXPIERENCED PAIN ON BACK OF LEFT KNEE. CALLED PHARMACIST AND PRIMARY DR AND BOTH TOLD HER HAD A HIGH CHANCE OF BEING AN ADVERSE REACTION TO MED. PAIN DID NOT GO AWAY . SHE WENT TO ORTHOPEDIC ON 10/28/21 AND WAS DIAGNOSED OF HAVING A BAKERS CYST. SHE CAME TO PHARMACY AND I INFORMED HER WE WILL FILL OUT VAERS FORM . SHE HAS NEVER RECEIVED THIS VACCINE OR A HIGH DOSE PREVIOUS TO THIS .
Age: 78.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Back pain, Breast pain, Lymphadenopathy, Neck pain, Pain
Clinical narrative: Error: Shoulder Joint Injury (prolonged pain, tingling, etc.)-
Age: 78.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Swelling
Clinical narrative: Error: Shoulder Joint Injury (prolonged pain, tingling, etc.)-
Age: 78.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Extra dose administered, Limb injury, Paraesthesia
Clinical narrative: Error: Shoulder Joint Injury (prolonged pain, tingling, etc.)-
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product administration error
Clinical narrative: Error: Wrong Dose of Vaccine - Too High-
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Incorrect dose administered
Clinical narrative: Error: Wrong Dose of Vaccine - Too High-
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cardiac imaging procedure abnormal, Chest pain, Headache, Myalgia, Myocarditis
Clinical narrative: is a 67 y/o F with a PMHx significant for hyperlipidemia, OSA (on CPAP), and osteoporosis who presented with chest pain and was ultimately found to have myocarditis, likely 2/2 her 3rd dose of the Moderna COVID vaccine. Her recent history is significant for 6 months of fatigue for which she has undergone workup with her PCP and felt to have CFS. On Saturday 10/23/21, she received the 3rd dose of the Moderna COVID vaccine around 1030 AM and began to notice full body myalgias by 3pm. She continued to experience severe, full body myalgias accompanied by fever/chills through that Sunday 10/24. She felt relatively well on Monday 10/25 however, on Tuesday 10/26 she developed severe central chest pressure that was pleuritic in nature. It was not positional nor exertional. Rated the pain as 5/10 at its worst. Pain radiates to back but not up her neck or down her L arm. There was no associated SOB, nausea/vomiting, diaphoresis. She did note DOE but this its unclear if this is related to her HPI or chronic, ongoing fatigue. She initially presented to urgent care and was noted to have a troponin elevation of 0.17 so she was sent to the ER. In the ER, she was mildly tachycardic to the low 100s. Repeat troponin was 0.26. ECG showed sinus tachycardia with slight PR depression in the inferior leads on my read. D-dimer was normal at 0.51. CRP was elevated at 7.3. Influenza, SARS-CoV-2, and RSV PCR testing was negative. CXR showed no acute cardiopulmonary abnormality. She was given aspirin, 1 L LR, and started on a heparin infusion for ACS r/o. Repeat troponin downtrended to 0.18-0.16. TTE demonstrated an LVEF 70%, grade I diastolic dysfunction, normal RV size and function, no wall motion or valvular abnormalities, trivial anterior pericardial effusion. Given suspicion for myocarditis, cMRI was obtained which showed normal LVEF and RVEF, non CAD scar (epicardial/midmyocardial) along the basal and mid inferior/inferolateral segments consistent with myocarditis and normal stress testing without evidence of inducible ischemia. She was initiated on Colchicine and discharged home with this. Pt's blood pressure not amendable to a BB. Follow up was scheduled with cardiology and primary care.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Nausea, Troponin increased
Clinical narrative: is a 67 y/o F with a PMHx significant for hyperlipidemia, OSA (on CPAP), and osteoporosis who presented with chest pain and was ultimately found to have myocarditis, likely 2/2 her 3rd dose of the Moderna COVID vaccine. Her recent history is significant for 6 months of fatigue for which she has undergone workup with her PCP and felt to have CFS. On Saturday 10/23/21, she received the 3rd dose of the Moderna COVID vaccine around 1030 AM and began to notice full body myalgias by 3pm. She continued to experience severe, full body myalgias accompanied by fever/chills through that Sunday 10/24. She felt relatively well on Monday 10/25 however, on Tuesday 10/26 she developed severe central chest pressure that was pleuritic in nature. It was not positional nor exertional. Rated the pain as 5/10 at its worst. Pain radiates to back but not up her neck or down her L arm. There was no associated SOB, nausea/vomiting, diaphoresis. She did note DOE but this its unclear if this is related to her HPI or chronic, ongoing fatigue. She initially presented to urgent care and was noted to have a troponin elevation of 0.17 so she was sent to the ER. In the ER, she was mildly tachycardic to the low 100s. Repeat troponin was 0.26. ECG showed sinus tachycardia with slight PR depression in the inferior leads on my read. D-dimer was normal at 0.51. CRP was elevated at 7.3. Influenza, SARS-CoV-2, and RSV PCR testing was negative. CXR showed no acute cardiopulmonary abnormality. She was given aspirin, 1 L LR, and started on a heparin infusion for ACS r/o. Repeat troponin downtrended to 0.18-0.16. TTE demonstrated an LVEF 70%, grade I diastolic dysfunction, normal RV size and function, no wall motion or valvular abnormalities, trivial anterior pericardial effusion. Given suspicion for myocarditis, cMRI was obtained which showed normal LVEF and RVEF, non CAD scar (epicardial/midmyocardial) along the basal and mid inferior/inferolateral segments consistent with myocarditis and normal stress testing without evidence of inducible ischemia. She was initiated on Colchicine and discharged home with this. Pt's blood pressure not amendable to a BB. Follow up was scheduled with cardiology and primary care.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood test, Bone pain, Cardiac stress test, Chest pain, Chills
Clinical narrative: is a 67 y/o F with a PMHx significant for hyperlipidemia, OSA (on CPAP), and osteoporosis who presented with chest pain and was ultimately found to have myocarditis, likely 2/2 her 3rd dose of the Moderna COVID vaccine. Her recent history is significant for 6 months of fatigue for which she has undergone workup with her PCP and felt to have CFS. On Saturday 10/23/21, she received the 3rd dose of the Moderna COVID vaccine around 1030 AM and began to notice full body myalgias by 3pm. She continued to experience severe, full body myalgias accompanied by fever/chills through that Sunday 10/24. She felt relatively well on Monday 10/25 however, on Tuesday 10/26 she developed severe central chest pressure that was pleuritic in nature. It was not positional nor exertional. Rated the pain as 5/10 at its worst. Pain radiates to back but not up her neck or down her L arm. There was no associated SOB, nausea/vomiting, diaphoresis. She did note DOE but this its unclear if this is related to her HPI or chronic, ongoing fatigue. She initially presented to urgent care and was noted to have a troponin elevation of 0.17 so she was sent to the ER. In the ER, she was mildly tachycardic to the low 100s. Repeat troponin was 0.26. ECG showed sinus tachycardia with slight PR depression in the inferior leads on my read. D-dimer was normal at 0.51. CRP was elevated at 7.3. Influenza, SARS-CoV-2, and RSV PCR testing was negative. CXR showed no acute cardiopulmonary abnormality. She was given aspirin, 1 L LR, and started on a heparin infusion for ACS r/o. Repeat troponin downtrended to 0.18-0.16. TTE demonstrated an LVEF 70%, grade I diastolic dysfunction, normal RV size and function, no wall motion or valvular abnormalities, trivial anterior pericardial effusion. Given suspicion for myocarditis, cMRI was obtained which showed normal LVEF and RVEF, non CAD scar (epicardial/midmyocardial) along the basal and mid inferior/inferolateral segments consistent with myocarditis and normal stress testing without evidence of inducible ischemia. She was initiated on Colchicine and discharged home with this. Pt's blood pressure not amendable to a BB. Follow up was scheduled with cardiology and primary care.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Echocardiogram, Magnetic resonance imaging, Myalgia, Myocardial necrosis marker, Myocarditis
Clinical narrative: is a 67 y/o F with a PMHx significant for hyperlipidemia, OSA (on CPAP), and osteoporosis who presented with chest pain and was ultimately found to have myocarditis, likely 2/2 her 3rd dose of the Moderna COVID vaccine. Her recent history is significant for 6 months of fatigue for which she has undergone workup with her PCP and felt to have CFS. On Saturday 10/23/21, she received the 3rd dose of the Moderna COVID vaccine around 1030 AM and began to notice full body myalgias by 3pm. She continued to experience severe, full body myalgias accompanied by fever/chills through that Sunday 10/24. She felt relatively well on Monday 10/25 however, on Tuesday 10/26 she developed severe central chest pressure that was pleuritic in nature. It was not positional nor exertional. Rated the pain as 5/10 at its worst. Pain radiates to back but not up her neck or down her L arm. There was no associated SOB, nausea/vomiting, diaphoresis. She did note DOE but this its unclear if this is related to her HPI or chronic, ongoing fatigue. She initially presented to urgent care and was noted to have a troponin elevation of 0.17 so she was sent to the ER. In the ER, she was mildly tachycardic to the low 100s. Repeat troponin was 0.26. ECG showed sinus tachycardia with slight PR depression in the inferior leads on my read. D-dimer was normal at 0.51. CRP was elevated at 7.3. Influenza, SARS-CoV-2, and RSV PCR testing was negative. CXR showed no acute cardiopulmonary abnormality. She was given aspirin, 1 L LR, and started on a heparin infusion for ACS r/o. Repeat troponin downtrended to 0.18-0.16. TTE demonstrated an LVEF 70%, grade I diastolic dysfunction, normal RV size and function, no wall motion or valvular abnormalities, trivial anterior pericardial effusion. Given suspicion for myocarditis, cMRI was obtained which showed normal LVEF and RVEF, non CAD scar (epicardial/midmyocardial) along the basal and mid inferior/inferolateral segments consistent with myocarditis and normal stress testing without evidence of inducible ischemia. She was initiated on Colchicine and discharged home with this. Pt's blood pressure not amendable to a BB. Follow up was scheduled with cardiology and primary care.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Anticoagulant therapy, Back pain, C-reactive protein increased, Cardiac imaging procedure abnormal, Cardiac stress test normal
Clinical narrative: is a 67 y/o F with a PMHx significant for hyperlipidemia, OSA (on CPAP), and osteoporosis who presented with chest pain and was ultimately found to have myocarditis, likely 2/2 her 3rd dose of the Moderna COVID vaccine. Her recent history is significant for 6 months of fatigue for which she has undergone workup with her PCP and felt to have CFS. On Saturday 10/23/21, she received the 3rd dose of the Moderna COVID vaccine around 1030 AM and began to notice full body myalgias by 3pm. She continued to experience severe, full body myalgias accompanied by fever/chills through that Sunday 10/24. She felt relatively well on Monday 10/25 however, on Tuesday 10/26 she developed severe central chest pressure that was pleuritic in nature. It was not positional nor exertional. Rated the pain as 5/10 at its worst. Pain radiates to back but not up her neck or down her L arm. There was no associated SOB, nausea/vomiting, diaphoresis. She did note DOE but this its unclear if this is related to her HPI or chronic, ongoing fatigue. She initially presented to urgent care and was noted to have a troponin elevation of 0.17 so she was sent to the ER. In the ER, she was mildly tachycardic to the low 100s. Repeat troponin was 0.26. ECG showed sinus tachycardia with slight PR depression in the inferior leads on my read. D-dimer was normal at 0.51. CRP was elevated at 7.3. Influenza, SARS-CoV-2, and RSV PCR testing was negative. CXR showed no acute cardiopulmonary abnormality. She was given aspirin, 1 L LR, and started on a heparin infusion for ACS r/o. Repeat troponin downtrended to 0.18-0.16. TTE demonstrated an LVEF 70%, grade I diastolic dysfunction, normal RV size and function, no wall motion or valvular abnormalities, trivial anterior pericardial effusion. Given suspicion for myocarditis, cMRI was obtained which showed normal LVEF and RVEF, non CAD scar (epicardial/midmyocardial) along the basal and mid inferior/inferolateral segments consistent with myocarditis and normal stress testing without evidence of inducible ischemia. She was initiated on Colchicine and discharged home with this. Pt's blood pressure not amendable to a BB. Follow up was scheduled with cardiology and primary care.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chest X-ray normal, Chest discomfort, Chest pain, Chills, Condition aggravated
Clinical narrative: is a 67 y/o F with a PMHx significant for hyperlipidemia, OSA (on CPAP), and osteoporosis who presented with chest pain and was ultimately found to have myocarditis, likely 2/2 her 3rd dose of the Moderna COVID vaccine. Her recent history is significant for 6 months of fatigue for which she has undergone workup with her PCP and felt to have CFS. On Saturday 10/23/21, she received the 3rd dose of the Moderna COVID vaccine around 1030 AM and began to notice full body myalgias by 3pm. She continued to experience severe, full body myalgias accompanied by fever/chills through that Sunday 10/24. She felt relatively well on Monday 10/25 however, on Tuesday 10/26 she developed severe central chest pressure that was pleuritic in nature. It was not positional nor exertional. Rated the pain as 5/10 at its worst. Pain radiates to back but not up her neck or down her L arm. There was no associated SOB, nausea/vomiting, diaphoresis. She did note DOE but this its unclear if this is related to her HPI or chronic, ongoing fatigue. She initially presented to urgent care and was noted to have a troponin elevation of 0.17 so she was sent to the ER. In the ER, she was mildly tachycardic to the low 100s. Repeat troponin was 0.26. ECG showed sinus tachycardia with slight PR depression in the inferior leads on my read. D-dimer was normal at 0.51. CRP was elevated at 7.3. Influenza, SARS-CoV-2, and RSV PCR testing was negative. CXR showed no acute cardiopulmonary abnormality. She was given aspirin, 1 L LR, and started on a heparin infusion for ACS r/o. Repeat troponin downtrended to 0.18-0.16. TTE demonstrated an LVEF 70%, grade I diastolic dysfunction, normal RV size and function, no wall motion or valvular abnormalities, trivial anterior pericardial effusion. Given suspicion for myocarditis, cMRI was obtained which showed normal LVEF and RVEF, non CAD scar (epicardial/midmyocardial) along the basal and mid inferior/inferolateral segments consistent with myocarditis and normal stress testing without evidence of inducible ischemia. She was initiated on Colchicine and discharged home with this. Pt's blood pressure not amendable to a BB. Follow up was scheduled with cardiology and primary care.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Echocardiogram, Ejection fraction, Electrocardiogram PR segment depression, Fatigue, Fibrin D dimer normal
Clinical narrative: is a 67 y/o F with a PMHx significant for hyperlipidemia, OSA (on CPAP), and osteoporosis who presented with chest pain and was ultimately found to have myocarditis, likely 2/2 her 3rd dose of the Moderna COVID vaccine. Her recent history is significant for 6 months of fatigue for which she has undergone workup with her PCP and felt to have CFS. On Saturday 10/23/21, she received the 3rd dose of the Moderna COVID vaccine around 1030 AM and began to notice full body myalgias by 3pm. She continued to experience severe, full body myalgias accompanied by fever/chills through that Sunday 10/24. She felt relatively well on Monday 10/25 however, on Tuesday 10/26 she developed severe central chest pressure that was pleuritic in nature. It was not positional nor exertional. Rated the pain as 5/10 at its worst. Pain radiates to back but not up her neck or down her L arm. There was no associated SOB, nausea/vomiting, diaphoresis. She did note DOE but this its unclear if this is related to her HPI or chronic, ongoing fatigue. She initially presented to urgent care and was noted to have a troponin elevation of 0.17 so she was sent to the ER. In the ER, she was mildly tachycardic to the low 100s. Repeat troponin was 0.26. ECG showed sinus tachycardia with slight PR depression in the inferior leads on my read. D-dimer was normal at 0.51. CRP was elevated at 7.3. Influenza, SARS-CoV-2, and RSV PCR testing was negative. CXR showed no acute cardiopulmonary abnormality. She was given aspirin, 1 L LR, and started on a heparin infusion for ACS r/o. Repeat troponin downtrended to 0.18-0.16. TTE demonstrated an LVEF 70%, grade I diastolic dysfunction, normal RV size and function, no wall motion or valvular abnormalities, trivial anterior pericardial effusion. Given suspicion for myocarditis, cMRI was obtained which showed normal LVEF and RVEF, non CAD scar (epicardial/midmyocardial) along the basal and mid inferior/inferolateral segments consistent with myocarditis and normal stress testing without evidence of inducible ischemia. She was initiated on Colchicine and discharged home with this. Pt's blood pressure not amendable to a BB. Follow up was scheduled with cardiology and primary care.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Influenza virus test negative, Left ventricular dysfunction, Myalgia, Myocarditis, Pain
Clinical narrative: is a 67 y/o F with a PMHx significant for hyperlipidemia, OSA (on CPAP), and osteoporosis who presented with chest pain and was ultimately found to have myocarditis, likely 2/2 her 3rd dose of the Moderna COVID vaccine. Her recent history is significant for 6 months of fatigue for which she has undergone workup with her PCP and felt to have CFS. On Saturday 10/23/21, she received the 3rd dose of the Moderna COVID vaccine around 1030 AM and began to notice full body myalgias by 3pm. She continued to experience severe, full body myalgias accompanied by fever/chills through that Sunday 10/24. She felt relatively well on Monday 10/25 however, on Tuesday 10/26 she developed severe central chest pressure that was pleuritic in nature. It was not positional nor exertional. Rated the pain as 5/10 at its worst. Pain radiates to back but not up her neck or down her L arm. There was no associated SOB, nausea/vomiting, diaphoresis. She did note DOE but this its unclear if this is related to her HPI or chronic, ongoing fatigue. She initially presented to urgent care and was noted to have a troponin elevation of 0.17 so she was sent to the ER. In the ER, she was mildly tachycardic to the low 100s. Repeat troponin was 0.26. ECG showed sinus tachycardia with slight PR depression in the inferior leads on my read. D-dimer was normal at 0.51. CRP was elevated at 7.3. Influenza, SARS-CoV-2, and RSV PCR testing was negative. CXR showed no acute cardiopulmonary abnormality. She was given aspirin, 1 L LR, and started on a heparin infusion for ACS r/o. Repeat troponin downtrended to 0.18-0.16. TTE demonstrated an LVEF 70%, grade I diastolic dysfunction, normal RV size and function, no wall motion or valvular abnormalities, trivial anterior pericardial effusion. Given suspicion for myocarditis, cMRI was obtained which showed normal LVEF and RVEF, non CAD scar (epicardial/midmyocardial) along the basal and mid inferior/inferolateral segments consistent with myocarditis and normal stress testing without evidence of inducible ischemia. She was initiated on Colchicine and discharged home with this. Pt's blood pressure not amendable to a BB. Follow up was scheduled with cardiology and primary care.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pericardial effusion, Pleuritic pain, Pyrexia, Respiratory syncytial virus test negative, SARS-CoV-2 test negative
Clinical narrative: is a 67 y/o F with a PMHx significant for hyperlipidemia, OSA (on CPAP), and osteoporosis who presented with chest pain and was ultimately found to have myocarditis, likely 2/2 her 3rd dose of the Moderna COVID vaccine. Her recent history is significant for 6 months of fatigue for which she has undergone workup with her PCP and felt to have CFS. On Saturday 10/23/21, she received the 3rd dose of the Moderna COVID vaccine around 1030 AM and began to notice full body myalgias by 3pm. She continued to experience severe, full body myalgias accompanied by fever/chills through that Sunday 10/24. She felt relatively well on Monday 10/25 however, on Tuesday 10/26 she developed severe central chest pressure that was pleuritic in nature. It was not positional nor exertional. Rated the pain as 5/10 at its worst. Pain radiates to back but not up her neck or down her L arm. There was no associated SOB, nausea/vomiting, diaphoresis. She did note DOE but this its unclear if this is related to her HPI or chronic, ongoing fatigue. She initially presented to urgent care and was noted to have a troponin elevation of 0.17 so she was sent to the ER. In the ER, she was mildly tachycardic to the low 100s. Repeat troponin was 0.26. ECG showed sinus tachycardia with slight PR depression in the inferior leads on my read. D-dimer was normal at 0.51. CRP was elevated at 7.3. Influenza, SARS-CoV-2, and RSV PCR testing was negative. CXR showed no acute cardiopulmonary abnormality. She was given aspirin, 1 L LR, and started on a heparin infusion for ACS r/o. Repeat troponin downtrended to 0.18-0.16. TTE demonstrated an LVEF 70%, grade I diastolic dysfunction, normal RV size and function, no wall motion or valvular abnormalities, trivial anterior pericardial effusion. Given suspicion for myocarditis, cMRI was obtained which showed normal LVEF and RVEF, non CAD scar (epicardial/midmyocardial) along the basal and mid inferior/inferolateral segments consistent with myocarditis and normal stress testing without evidence of inducible ischemia. She was initiated on Colchicine and discharged home with this. Pt's blood pressure not amendable to a BB. Follow up was scheduled with cardiology and primary care.